IRVINE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today announced that it has added Harry L. Leider, MD, MBA to its Strategic Advisor Board, which is chaired by Edward W. (Ned) Barnholt.

Until recently, Dr. Leider served as Chief Medical Officer (CMO) and Group Vice President of Walgreens.  As the CMO at Walgreens, he provided executive leadership for health analytics, clinical program development, and clinical sales solutions.  Dr. Leider also served as the senior clinical spokesperson for the company and routinely represented Walgreens with leaders in government, managed care, health systems, and other healthcare organizations.  As Chief Medical Officer, he led a cross-functional department of over 40 professionals that conducted over 60 health outcomes studies that demonstrated the value of Walgreens programs and services.  He also had leadership responsibility for a team that evaluated over 200 emerging healthcare technologies to provide information about potential M & A and partnership opportunities. Notably, Dr. Leider also directed the clinical design for a digital health programs that rewards 3 million Walgreens customers for taking steps to improve their health.

Prior to Walgreens, Dr. Leider was the Chief Medical Officer of Ameritox which was the nation’s largest specialty lab serving clinicians who treat chronic pain and behavioral health conditions. He was responsible for the development of all provider support and research programs, and played a key role supporting sales efforts directed at providers and payors.  Prior to his role at Ameritox, Dr. Leider held C-suite positions in several population health and payor companies.

"Biomerica’s unique InFoods®IBS diagnostic guided therapy now in trials in the United States, could help alleviate suffering in many of the 45 Million Americans that suffer from Irritable Bowel Syndrome (IBS)," stated Dr. Leider. 

Zackary Irani, Chairman and Chief Executive Officer, stated, “We are excited to have Harry join our Strategic Advisory Board.  His expertise and recognized leadership in cutting edge healthcare will be invaluable in helping us launch the InFoods® IBS product worldwide once approved.”

About Biomerica (NASDAQ:BMRA)

Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing.

The Biomerica InFoods® IBS product identifies patient specific foods that when removed may alleviate an individual's IBS symptoms. This patent-pending, diagnostic-guided therapy is designed to allow for a patient specific, guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is available for InFoods® diagnostic products. Since the InFoods® product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, prospects, new products, favorable outlook, new distributors, expansion, increases in productivity and margins, expected orders, leading market positions, anticipated future sales or production volume of the Company, the launch or success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.

Contact(s):

Zack Irani | CEO
p. 949.645.2111
www.biomerica.com